Gene therapy safety study for neovascular macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new gene therapy drug (KH631) to see if it is safe and tolerated in people with neovascular age-related macular degeneration (nAMD). It may help your retina problems, but the early goal is mainly to learn about side effects and how the treatment behaves in the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign the consent form and are willing to follow study instructions
- You are age 50 to 85 and have been diagnosed with nAMD
- In the past 6 months, you had at least 3 anti-VEGF injections and are still on active treatment
- Your eye scans and vision results suggest you responded in a specific way to anti-VEGF treatment
- Your study eye has an intraocular lens implant for at least 3 months (pseudophakic)
- You do not have certain eye conditions (like other causes of abnormal vessel growth, retinal detachment history, or uncontrolled glaucoma)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
This study tests an investigational gene therapy (called CRISPR/Cas13) given as an injection into the eye for people with wet age-related macular degeneration (nAMD). It aims to see if the treatment is safe and if it can help by targeting the cause of the disease.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.